AzTrials
AzTrials

Iron DeficiencyNCT07394088

Assessing Clinical Impact of AI for Iron Deficiency

A study testing AI Risk Display in people with Iron Deficiency and Iron Deficiency Anemias, run by China Medical University Hospital at 1 site in Taiwan.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this clinical trial is to evaluate whether an AI-based risk notification system integrated into routine clinical care can improve the clinical detection of iron deficiency in adult patients attending Internal Medicine, Family Medicine, and Hematology/Oncology clinics at China Medical University Hospital in… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Iron Deficiency, Iron Deficiency Anemias
What is being tested?
AI Risk Display
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,196 participants
Where
1 siteTaiwan
Study dates
1 Apr 2026to Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18 years or older.
  • Patients attending outpatient clinics of participating departments including 2.1. Internal Medicine, 2.2 Family Medicine 2.3. Hematology/Oncology
  • Completion of a routine complete blood count (CBC) as part of usual clinical care during the outpatient encounter.
  • Availability of the CBC report in the institutional laboratory information system, allowing sufficient data for analysis.

Who cannot join

  • Encounters with missing or incomplete key identifiers (e.g., patient identification number, ) that prevent determination of exposure status (AI information displayed vs not displayed) or assessment of outcomes within the defined follow-up period.
  • Encounters without a valid department code required by the information system to trigger the randomization mechanism and AI risk display.
  • Encounters with incomplete or missing laboratory data required to activate the AI system.
  • Repeated CBC encounters from the same patient during the study period, if applicable; only the first eligible encounter will be included to avoid duplication.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Taiwan1 site, 1 recruiting
  • China Medical University Hospital

    Taichung, 404

    Yu-Hsin Chang, +886 422052121 ext. 12587, 028702@tool.caaumed.org.tw

    Recruiting

Other trials in Taiwan

About this study

Official title: Evaluation of the Clinical Impact of Machine Learning-Based Risk Classification Using Blood Analysis on Iron Deficiency Detection

The goal of this clinical trial is to evaluate whether an AI-based risk notification system integrated into routine clinical care can improve the clinical detection of iron deficiency in adult patients attending Internal Medicine, Family Medicine, and Hematology/Oncology clinics at China Medical University Hospital in Taiwan.

The main questions this study aims to answer are:

Read more
  1. Does displaying AI-generated iron deficiency risk classification to physicians increase the overall detection rate of iron deficiency at the population level?
  2. Does the AI-based risk notification influence physicians' diagnostic behavior by increasing the rate at which ferritin testing is ordered specifically for suspected iron deficiency?
  3. Among ferritin tests ordered for suspected iron deficiency, does the diagnostic yield (positivity rate) remain appropriate, reflecting efficient use of testing resources?
  4. Are the effects of the AI-assisted intervention consistent among patients with anemia and without anemia?

Comparison Groups Researchers will compare clinical encounters in which physicians receive AI-generated iron deficiency risk information (the Prompt Group) with encounters in which physicians receive standard laboratory results without AI risk display (the Control Group). The comparison focuses on differences in iron deficiency detection, ferritin ordering behavior for suspected iron deficiency, and diagnostic yield.

What Participants Will Experience

  1. No Additional Procedures: As this is a pragmatic study embedded in routine clinical care, participants will not undergo any additional blood draws, invasive procedures, or clinic visits beyond standard care.
  2. Routine Care Only: Patients attend their scheduled outpatient visits and receive complete blood count (CBC) testing as ordered by their treating physician, independent of study participation.
  3. Background Data Integration: The AI system operates within the hospital's information system, analyzing routinely collected CBC data after results become available. No additional data entry or action is required from patients.
  4. Physician Autonomy Preserved:

The AI provides a non-mandatory risk classification as decision support. For patients identified as high risk, the system may display an informational prompt suggesting consideration of iron-related testing if no recent testing is found. All diagnostic and management decisions remain entirely at the discretion of the treating physician.

Read the detailed description

Detailed Description: Machine Learning-Based Risk Notification for Iron Deficiency

  1. Study Overview and Design This is a single-center, prospective, pragmatic randomized controlled trial (pRCT) conducted at China Medical University Hospital (CMUH) in Taiwan. The study aims to evaluate the clinical impact of a machine learning-based clinical decision support tool on iron deficiency detection and related diagnostic behavior in a real-world outpatient setting. Unlike traditional explanatory trials with restrictive protocols, this pragmatic design integrates the intervention directly into the existing Electronic Health Record (EHR) system.
  2. Participant Population The study includes adult patients (aged 18 years or older) receiving outpatient care in the following departments at CMUH:
  3. Division of General Internal Medicine
  4. Department of Family Medicine
  5. Division of Hematology and Oncology All eligible outpatient encounters in which a routine complete blood count (CBC) test is performed as part of standard clinical care are included. No additional tests or procedures are required for study participation.
  6. AI Intervention and Clinical Workflow The AI model used in this study estimates the risk of iron deficiency based on routinely available CBC parameters. The randomization and intervention occur automatically within the EHR system after CBC results become available. Randomization: Following completion of the CBC, each eligible encounter is automatically assigned, according to a predefined randomization mechanism, to either the Prompt Group or the Control Group. Randomization occurs prior to physician review of laboratory results. Prompt Group (Intervention): Physicians are shown an informational "AI Risk Hint," categorizing the patient as either high risk or low risk for iron deficiency, displayed on the laboratory results interface. For patients classified as high risk, the system automatically checks whether iron-related testing has been performed within the previous 30 days. If no recent testing is identified, an informational prompt suggests consideration of iron-related laboratory evaluation. Control Group: Physicians review laboratory results according to usual clinical practice, without display of AI-generated risk information or prompts. Clinical Independence: The AI system functions solely as a decision support tool. It does not generate orders, mandate testing, or recommend specific treatments. All clinical decisions, including whether to order follow-up iron studies (e.g., ferritin or other iron indices), remain entirely at the discretion of the treating physician.
  7. Outcome Measures 4.1 Primary Outcome: Overall iron deficiency detection rate, defined as the proportion of patients identified as having iron deficiency among all eligible encounters. 4.2 Secondary Outcomes: 4.2.1 Iron deficiency detection rate among patients with anemia The proportion of patients with anemia who are subsequently confirmed to have iron deficiency among all anemic patients included in the study. 4.2.2 Iron deficiency detection rate among patients without anemia The proportion of patients without anemia who are subsequently confirmed to have iron deficiency among all non-anemic patients included in the study. 4.2.3 Rate of ferritin testing for suspected iron deficiency, defined as the proportion of encounters in which ferritin testing is ordered with the indication "to confirm iron deficiency" within 1 month after the CBC report becomes available. 4.2.4 Marginal diagnostic yield of ferritin testing attributable to AI-assisted prompting This measure reflects the average additional number of iron deficiency diagnoses obtained per additional ferritin test attributable to AI-assisted decision support, defined as the difference in confirmed diagnoses between the AI-assisted group and the control group divided by the difference in ferritin tests ordered between the two groups. 4.2.5 Incremental cost-effectiveness of AI-assisted iron deficiency detection This outcome represents the additional cost required to identify one additional case of iron deficiency attributable to AI-assisted decision support.
  8. Risk Mitigation and Ethical Considerations This outcome represents the additional cost required to identify one additional case of iron deficiency attributable to AI-assisted decision support, calculated as the difference in ferritin testing costs between the AI-assisted group and the control group divided by the difference in confirmed iron deficiency diagnoses between the two groups.

Data Privacy:

All data processing and analysis are conducted within CMUH's secure internal systems in accordance with institutional policies and local regulatory requirements. No identifiable patient data are transmitted outside the hospital environment.

Being tested
AI Risk Display
Keywords
machine learning, complete blood count, iron deficiency, pragmatic randomized trial, detection rate
Medical subject headings
Iron Deficiencies, Anemia, Iron-Deficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AI Risk DisplayOther

    Participants in this group receive AI-generated information showing their high or low risk of iron deficiency to assist clinical decision-making. For participants identified as high-risk, the system automatically checks for iron-related tests performed in the past 30 days and alerts the physician if no recent tests are found. The final decision to order any tests remains with the physician.

Study groups in NCT07394088
Study groupRoleWhat they receive
AI displayExperimentalNot described
Receives: Other: AI Risk Display
ControlNo interventionNot described

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Detection Rate of Iron Deficiency

    The primary outcome is the proportion of patients with laboratory-confirmed iron deficiency identified during routine clinical care.

    Iron deficiency is determined based on routine iron-related laboratory tests, such as ferritin, as ordered by the treating physician according to usual clinical practice.

    The detection rate is calculated as the number of patients diagnosed with iron deficiency divided by the total number of patients undergoing complete blood count testing during the study period.

    Measured: Within 1 month after the complete blood count report is available

Secondary outcomes (5)
  1. Iron Deficiency Detection Rate in Patients With Anemia

    The proportion of patients with anemia who are subsequently identified as having iron deficiency based on standard iron-related laboratory tests ordered during routine clinical care.

    Measured: Within 1 month after the complete blood count report becomes available

  2. Iron Deficiency Detection Rate in Patients Without Anemia

    The proportion of patients without anemia who are identified as having iron deficiency based on standard iron-related laboratory tests ordered during routine clinical care.

    Measured: Within 1 month after the complete blood count report becomes available

  3. Rate of iron-related laboratory testing for suspected iron deficiency

    The proportion of eligible encounters in which iron-related laboratory testing is ordered with the indication "to confirm iron deficiency" within 1 month after the CBC report becomes available.

    Measured: Within 1 month after the complete blood count (CBC) report becomes available

  4. Incremental number of confirmed iron deficiency diagnoses per additional iron-related laboratory test attributable to AI-assisted decision support

    The incremental diagnostic yield was defined as the difference in the number of confirmed iron deficiency cases between the AI-assisted group and the control group, divided by the difference in the number of iron-related laboratory tests ordered between the two groups. This measure reflects the average additional number of diagnoses obtained per additional test attributable to AI-assisted risk prompting.

    Measured: Within 1 month after the complete blood count (CBC) report becomes available

  5. Incremental cost-effectiveness

    The incremental cost-effectiveness ratio was defined as the difference in total iron-related laboratory testing costs between the AI-assisted group and the control group, divided by the difference in the number of confirmed iron deficiency cases identified between the two groups.

    Measured: Within 1 month after the complete blood count report is available

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Feb 2026
  2. Study start1 Apr 2026
  3. Primary completion31 Dec 2026 (estimated)
  4. Study completionMar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a pragmatic, randomized, parallel-assignment interventional study. Participants are randomly allocated to parallel groups to evaluate the intervention under real-world clinical conditions.
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
2,196 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07394088
Sponsor's protocol ID
CMUH115-REC2-004
Status last verified
May 2026
First submitted
30 Jan 2026
Last updated
26 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing AI Risk Display in people with Iron Deficiency and Iron Deficiency Anemias, run by China Medical University Hospital at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Detection Rate of Iron Deficiency (time frame: Within 1 month after the complete blood count report is available). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in